Table 1.
Demographic overview of the treatment-experienced patients starting an integrase inhibitor (INSTI)-based regimen
| Second-line | Highly experienced | |||||||
|---|---|---|---|---|---|---|---|---|
| Viral suppression | Viral failure | Viral suppression | Viral failure Salvage | |||||
| n = 148 | n = 51 | n = 260 | n = 139 | |||||
| n | % | n | % | n | % | n | % | |
| Age | ||||||||
| ≤30 | 6 | 4 | 2 | 4 | 1 | <0.4 | 0 | NA |
| 31–40 | 28 | 19 | 6 | 12 | 17 | 7 | 10 | 7 |
| 41–50 | 56 | 38 | 23 | 45 | 90 | 35 | 62 | 45 |
| 51+ | 58 | 39 | 20 | 39 | 152 | 58 | 67 | 48 |
| Median [IQR] | 47.8 | [41.4, 54.5] | 48.1 | [42.2, 53.4] | 53.3 | [46.9, 60.7] | 50.1 | [45.5, 55.0] |
| Sex | ||||||||
| Female | 6 | 4 | 2 | 4 | 16 | 6 | 8 | 6 |
| Male | 142 | 96 | 49 | 96 | 243 | 93 | 131 | 94 |
| Transgender | 0 | NA | 0 | NA | 1 | <0.4 | 0 | NA |
| Mode of HIV exposure | ||||||||
| Homosexual contact | 120 | 81 | 37 | 73 | 207 | 80 | 110 | 79 |
| Heterosexual contact | 23 | 16 | 10 | 20 | 28 | 11 | 15 | 11 |
| IDU | 2 | 1 | 0 | NA | 17 | 7 | 8 | 6 |
| Other/Unknown | 3 | 2 | 4 | 8 | 8 | 3 | 6 | 4 |
| HCV (ever) | ||||||||
| No/not tested | 131 | 89 | 47 | 92 | 225 | 87 | 121 | 87 |
| Yes | 17 | 11 | 4 | 8 | 35 | 13 | 18 | 13 |
| HBVsAg (ever) | ||||||||
| No/not tested | 145 | 98 | 48 | 94 | 244 | 94 | 138 | 99 |
| Yes | 3 | 2 | 3 | 6 | 16 | 6 | 1 | 1 |
| Total time on treatment (years) | ||||||||
| 0–5 | 86 | 58 | 29 | 57 | 24 | 9 | 23 | 17 |
| 6–10 | 36 | 24 | 10 | 20 | 60 | 23 | 22 | 16 |
| >10 | 26 | 18 | 12 | 24 | 176 | 68 | 94 | 68 |
| Median [IQR] | 4.4 | [2.1, 8.8] | 3.8 | [1.2, 9.6] | 12.7 | [9.3, 15.9] | 11.8 | [8.6, 14.0] |
| CD4 at INSTI initiation (cells/µl) | ||||||||
| ≤200 | 7 | 5 | 14 | 27 | 21 | 8 | 41 | 30 |
| 201–350 | 11 | 7 | 12 | 24 | 34 | 13 | 35 | 25 |
| 351–500 | 27 | 18 | 13 | 25 | 37 | 14 | 29 | 21 |
| ≥501 | 72 | 49 | 12 | 24 | 115 | 44 | 34 | 24 |
| Missing | 31 | 21 | 0 | NA | 53 | 20 | 0 | NA |
| Median [IQR] | 572.0 | [440.0, 778.0] | 340.0 | [190.0, 480.0] | 540.0 | [330.0, 792.0] | 330.0 | [180.0, 500.0] |
| Viral load at INSTI initiation (copies/mL) | ||||||||
| ≤50 | 111 | 75 | 0 | NA | 200 | 77 | 0 | NA |
| 51–10 000 | 0 | NA | 25 | 49 | 0 | NA | 85 | 61 |
| ≥10 001 | 0 | NA | 26 | 51 | 0 | NA | 54 | 39 |
| Missing | 37 | 25 | 0 | NA | 60 | 23 | 0 | NA |
| Median [IQR] | 40.0 | [37.0, 50.0] | 18700.0 | [375.0, 63000.0] | 44.5 | [39.0, 50.0] | 5290.0 | [600.0, 57600.0] |
| Mono/duo therapy past | ||||||||
| Yes | 62 | 42 | 23 | 45 | 222 | 85 | 110 | 79 |
| No | 86 | 58 | 28 | 55 | 38 | 15 | 29 | 21 |
| Year of HIV diagnosis | ||||||||
| ≤1990 | 23 | 16 | 11 | 22 | 115 | 44 | 56 | 40 |
| 1990–1999 | 38 | 26 | 9 | 18 | 115 | 44 | 65 | 47 |
| ≥2000 | 73 | 49 | 26 | 51 | 22 | 8 | 15 | 11 |
| Missing | 14 | 9 | 5 | 10 | 8 | 3 | 3 | 2 |
| Year of ART initiation | ||||||||
| 1996–1999 | 37 | 25 | 17 | 33 | 217 | 83 | 116 | 83 |
| 2000–2006 | 45 | 30 | 14 | 27 | 33 | 13 | 10 | 7 |
| 2007–2013 | 66 | 45 | 20 | 39 | 10 | 4 | 13 | 9 |
IDU, injecting drug use; IQR, interquartile range; HCV, hepatitis C virus co-infection; HBVsAG, hepatitis B virus (surface antigen) co-infection; ART, antiretroviral therapy; NA, not applicable